264 related articles for article (PubMed ID: 16160062)
1. HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation.
Zeng L; Xu H; Chew TL; Eng E; Sadeghi MM; Adler S; Kanwar YS; Danesh FR
FASEB J; 2005 Nov; 19(13):1845-7. PubMed ID: 16160062
[TBL] [Abstract][Full Text] [Related]
2. HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation.
Xu H; Zeng L; Peng H; Chen S; Jones J; Chew TL; Sadeghi MM; Kanwar YS; Danesh FR
Am J Physiol Renal Physiol; 2006 Nov; 291(5):F995-1004. PubMed ID: 16774905
[TBL] [Abstract][Full Text] [Related]
3. Rho and ROCK signaling in VEGF-induced microvascular endothelial hyperpermeability.
Sun H; Breslin JW; Zhu J; Yuan SY; Wu MH
Microcirculation; 2006; 13(3):237-47. PubMed ID: 16627366
[TBL] [Abstract][Full Text] [Related]
4. Thrombin-induced phosphorylation of the regulatory light chain of myosin II in cultured bovine corneal endothelial cells.
Satpathy M; Gallagher P; Lizotte-Waniewski M; Srinivas SP
Exp Eye Res; 2004 Oct; 79(4):477-86. PubMed ID: 15381032
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin stimulates vascular endothelial growth factor production by hypoxia-inducible factor-1alpha upregulation in endothelial cells.
Nishimoto-Hazuku A; Hirase T; Ide N; Ikeda Y; Node K
J Cardiovasc Pharmacol; 2008 Mar; 51(3):267-73. PubMed ID: 18356691
[TBL] [Abstract][Full Text] [Related]
6. How increased VEGF induces glomerular hyperpermeability: a potential signaling pathway of Rac1 activation.
Peng H; Wang C; Ye ZC; Chen YR; Zhang J; Chen ZJ; Yu XQ; Lou TQ
Acta Diabetol; 2010 Dec; 47 Suppl 1():57-63. PubMed ID: 19404567
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors.
Kusama T; Mukai M; Iwasaki T; Tatsuta M; Matsumoto Y; Akedo H; Nakamura H
Cancer Res; 2001 Jun; 61(12):4885-91. PubMed ID: 11406567
[TBL] [Abstract][Full Text] [Related]
8. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
Danesh FR; Kanwar YS
FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
[TBL] [Abstract][Full Text] [Related]
9. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin.
Jacobson JR; Dudek SM; Birukov KG; Ye SQ; Grigoryev DN; Girgis RE; Garcia JG
Am J Respir Cell Mol Biol; 2004 May; 30(5):662-70. PubMed ID: 14630613
[TBL] [Abstract][Full Text] [Related]
10. MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway.
Hiraoka M; Nitta N; Nagai M; Shimokado K; Yoshida M
Life Sci; 2004 Jul; 75(11):1333-41. PubMed ID: 15234191
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin alleviates hyperpermeability of glomerular endothelial cells in early-stage diabetic nephropathy by inhibition of RhoA/ROCK1.
Peng H; Luo P; Li Y; Wang C; Liu X; Ye Z; Li C; Lou T
PLoS One; 2013; 8(11):e80009. PubMed ID: 24244596
[TBL] [Abstract][Full Text] [Related]
12. Laminar shear stress prevents simvastatin-induced adhesion molecule expression in cytokine activated endothelial cells.
Rossi J; Rouleau L; Emmott A; Tardif JC; Leask RL
Eur J Pharmacol; 2010 Dec; 649(1-3):268-76. PubMed ID: 20863785
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation.
Lee MH; Cho YS; Han YM
Stem Cells; 2007 Jul; 25(7):1654-63. PubMed ID: 17464088
[TBL] [Abstract][Full Text] [Related]
14. Neuregulin1-β decreases interleukin-1β-induced RhoA activation, myosin light chain phosphorylation, and endothelial hyperpermeability.
Wu L; Ramirez SH; Andrews AM; Leung W; Itoh K; Wu J; Arai K; Lo EH; Lok J
J Neurochem; 2016 Jan; 136(2):250-7. PubMed ID: 26438054
[TBL] [Abstract][Full Text] [Related]
15. HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation.
Al-Haidari AA; Syk I; Thorlacius H
Biochem Biophys Res Commun; 2014 Mar; 446(1):68-72. PubMed ID: 24582560
[TBL] [Abstract][Full Text] [Related]
16. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(5):1019-21. PubMed ID: 16188392
[TBL] [Abstract][Full Text] [Related]
17. Statin therapy influences endothelial cell morphology and F-actin cytoskeleton structure when exposed to static and laminar shear stress conditions.
Dick M; Jonak P; Leask RL
Life Sci; 2013 May; 92(14-16):859-65. PubMed ID: 23517776
[TBL] [Abstract][Full Text] [Related]
18. RhoA and NF-κB are involved in lipopolysaccharide-induced brain microvascular cell line hyperpermeability.
He F; Peng J; Deng XL; Yang LF; Wu LW; Zhang CL; Yin F
Neuroscience; 2011 Aug; 188():35-47. PubMed ID: 21575689
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation.
Pala L; Cresci B; Manuelli C; Maggi E; Yamaguchi YF; Cappugi P; Rotella CM; Giannini S
Microvasc Res; 2005 Nov; 70(3):179-88. PubMed ID: 16271941
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin Ameliorates Matrix Stiffness-Mediated Endothelial Monolayer Disruption.
Lampi MC; Faber CJ; Huynh J; Bordeleau F; Zanotelli MR; Reinhart-King CA
PLoS One; 2016; 11(1):e0147033. PubMed ID: 26761203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
